Alnylam to launch larger study of RNA therapy for Huntington’s disease

Alnylam Therapeutics announced it will expand its clinical program for an RNA‑based drug aimed at treating Huntington’s disease.

The decision comes amid a challenging landscape for neurodegenerative therapies, where recent efforts, such as Roche’s study, failed to convert promising biomarker signals into clinical benefit.

Despite these setbacks, Alnylam is moving forward with a bigger trial, underscoring its commitment to pursuing RNA approaches for this difficult condition.

The company did not disclose additional details about the trial design or timelines in the announcement.